Navigation Links
Gene Marker May Improve Odds of Stem Cell Therapies for Disease
Date:1/9/2009

PHILADELPHIA, Jan. 9 /PRNewswire-USNewswire/ -- A single tumor-suppressor gene may provide a unique marker for senescence in Mesenchymal stem cells (MSCs) in vitro, while also playing a role in moving MSCs into senescence, researchers at the Human Health Foundation and the Sbarro Institute for Cancer Research and Molecular Medicine report. Their work was published in Stem Cells and Development.

The finding is important, since MSCs are currently being tested in cell and gene therapy for a number of human diseases.

When injected into the body, MSCs have the unique ability to differentiate into a variety of cells. But before they can be employed for therapeutic uses, the stem cells must be cultivated in vitro. During this process, MSCs are often compromised when they enter senescence, or aging, which limits their capacity to proliferate and differentiate into new tissues, making them useless for treatment.

In the current study, researchers studied senescent MSCs drawn from rats in vitro. MSCs in senescence showed a downregulation, or decrease, in several genes involved in stem cell self-renewal and DNA repair, including Rb1 and p107 gene expression.

However, pRB2/p130, a tumor suppressor gene first identified by Antonio Giordano, Director of the Sbarro Institute for Cancer Research and Molecular Medicine at the College of Science and Technology at Temple University and a "Chiara Fama" Professor at the University of Siena, Italy, and a co-author of the paper, became the prominent RB protein.

"By studying the process of senescence in MSCs we have arrived at new possibilities to improve the therapeutic capabilities of the stem cells in transplantation," said Giordano.

"The presence of Rb2 during senescence raises the possibility it may provide an early marker of the process," said co-author Umberto Galderisi, a Professor at the University of Naples and an Adjunct Associate Professor at the Sbarro Institute for Cancer Research and Molecular Medicine at Temple University. "Next we will work to confirm our data by seeing the impact when Rb2 is silenced in these stem cells."

The Human Health Foundation (HHF) (www.hhfonlus.org) is a nonprofit organization designed to develop and fund biomedical research in Italy. Along with developing new medical research centers, HHF promotes and supports novel methods for the prevention, diagnosis and treatment of cancer and other illnesses; implements and designs new initiatives to exchange and spread the results of new research; and design original programs to inform and increase public awareness of health and research issues.

Sbarro Health Research Organization (www.shro.org), a leader in cancer, cardiovascular, and diabetes research, a nonprofit charitable organization, supports the Sbarro Institute for Cancer Research and Molecular Medicine located at Temple University in Philadelphia.

This news release was issued on behalf of Newswise(TM). For more information, visit http://www.newswise.com.


'/>"/>
SOURCE Sbarro Health Research Organization
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
2. BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP-1 Gene in Multiple Cancer Types
3. CV Therapeutics Anti-Ischemic Agent Ranexa(R) Significantly Reduces HbA1c and Other Markers of Diabetes in MERLIN TIMI-36
4. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
5. BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data
6. Orion Genomics Announces the Discovery of Novel Breast Cancer Biomarkers
7. QIAGEN and Center for Molecular Medicine Create Research Collaboration for Molecular Diagnostic Markers for Breast Cancer, Other Womens Health Issues
8. Vermillions Biomarkers Prove Beneficial in Identifying Women With Ovarian Cancer and Detecting Early-Stage Disease
9. Gene Hunters Fine-Tune Marker for Common Obesity Gene
10. EnVivo Pharmaceuticals Announces Initiation of Clinical Safety and Biomarker Study of Alpha-7 Nicotinic Agonist, EVP-6124, in Patients with Schizophrenia
11. Biomarkers May Reduce the Need for Biopsies and Offer Personalized Care for Heart and Lung Transplant Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... 2017 Provides understanding and access to ... into by the worlds leading healthcare companies. ... Description The Global Renal Failure Partnering Terms and ... to partnering deals and agreements entered into by ... Trends in partnering deals - Top deals ...
(Date:2/20/2017)... 20, 2017 The report analyzes the worldwide markets for Drug-Eluting ... the US, Canada , Japan ... Latin America , and Rest of World. ... ... provided for the period 2015 through 2022. Also, a six-year historic ...
(Date:2/20/2017)... Feb. 20, 2017 This report analyzes the worldwide ... report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , and Rest ... http://www.reportlinker.com/p04707131-summary/view-report.html Annual estimates and forecasts are provided ... analysis is provided for these markets. Market data and analytics ...
Breaking Medicine Technology:
(Date:2/20/2017)... ... February 20, 2017 , ... Scrubbing in for his first ... Dr. Christopher Pezzi remembers the excitement of the surgeon training him. , “He was ... to do this? Don’t tell anyone, but I would do it for free,’” Dr. ...
(Date:2/20/2017)... ... 2017 , ... Today, Biscom , the leader in ... IoT device from Biscom designed to deliver confidential patient information securely and quickly, ... HIMSS17 and will be conducting demonstrations at Booth #374. , With ...
(Date:2/20/2017)... , ... February 20, 2017 , ... Johns Hopkins All ... education building. A topping out ceremony on Friday marked the halfway point of construction ... to open in Fall 2018, will serve as a center for innovation aimed at ...
(Date:2/19/2017)... (PRWEB) , ... February 19, 2017 , ... Braun Industries ... JEMS Conference & Exposition, the event will take place February 23-25, 2017 at the ... will be in Booth #909 with three new ambulances on display. ...
(Date:2/18/2017)... ... February 17, 2017 , ... Focused start-ups, not traditional health ... according to the recent NEJM Catalyst Insights Report on the New Marketplace. ... Insights Council, a qualified group of U.S. executives, clinical leaders, and clinicians at ...
Breaking Medicine News(10 mins):